•  
sterna biologicals home

Clinical Trials

Sterna biologicals conducts clinical trials to advance its development pipeline. Our lead compound, SB010 for moderate and severe Th2-driven asthma, successfully completed Phase IIa development in 2014.

 

CompoundIndicationPhaseDescriptionStatusFurther Details
SB010 Asthma

I

Single dose

completed

Press Release (07-NOV-2011)

Press Release (27-FEB-2012)

   

I

Multiple dose

completed

 
   

I

Safety in asthmatics

completed

Press Release (11-SEP-2012)

   

IIa

Proof-of-Concept

completed

 Press Release (21-FEB-2014)
  eCOPD

IIa

Pilot Proof-of-Concept

ongoing

 
SB011

Atopic Dermatitis

IIa

Proof-of-Concept

ongoing

 
SB012

Ulcerative Colitis

IIa

Proof-of-Concept

ongoing

 

 

We also report results of registered clinical trials to www.clinicaltrials.gov.

© sterna biologicals GmbH & Co. KG • Bismarckstraße 7 • D-35037 Marburg